US Pharma MarketingLife Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events. Physicians rare diseases education Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Saved Stories Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Summit Search Log In Try STAT+ My Account My Account Settings Saved Stories Billing History Home Newsletter The Readout Life…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
This is the Readout. Please read it.
And don’t miss us too much Monday, when the newsletter will be paused for the holiday. We’ll be back in your inbox Tuesday.
Source: STAT News Pharma